Hjem › Lymfom
Lymfom kliniske forsøg rekrutterer i USA
142 studier for Lymfom rekrutterer deltagere på steder over hele USA.
Byer med flest studier
- Houston, TX34 studier
- Boston, MA33 studier
- New York City, NY33 studier
- Washington, DC23 studier
- Baldwin Park, CA21 studier
- Chicago, IL20 studier
- Durham, NC17 studier
- St. Louis, MO15 studier
- Philadelphia, PA15 studier
- Cleveland, OH14 studier
- Edison, NJ12 studier
- Atlanta, GA12 studier
- Seattle, WA12 studier
- Salt Lake City, UT11 studier
- Rochester, MN11 studier
- Columbus, OH11 studier
- Nashville, TN11 studier
- Miami, FL11 studier
- Los Angeles, CA10 studier
- Pittsburgh, PA10 studier
- Dallas, TX10 studier
- Queens, NY10 studier
- Mountain View, CA9 studier
- Denver, CO9 studier
- Portland, OR9 studier
- Greenburgh, NY9 studier
- Milwaukee, WI9 studier
- Aurora, CO8 studier
- Birmingham, AL8 studier
- East Norwalk, CT8 studier
- Staten Island, NY8 studier
- Cincinnati, OH8 studier
- San Antonio, TX7 studier
- New Haven, CT7 studier
- Tampa, FL7 studier
- New Rochelle, NY7 studier
- Omaha, NE7 studier
- Phoenix, AZ7 studier
- Kansas City, MO6 studier
- Baltimore, MD6 studier
Efter delstat
- Alabama9 studier
- Arizona11 studier
- Arkansas3 studier
- Californien40 studier
- Colorado16 studier
- Connecticut7 studier
- District of Columbia7 studier
- Florida25 studier
- Georgia16 studier
- Illinois23 studier
- Indiana6 studier
- Iowa6 studier
- Kansas7 studier
- Kentucky5 studier
- Maryland21 studier
- Massachusetts33 studier
- Michigan12 studier
- Minnesota14 studier
- Missouri17 studier
- Nebraska7 studier
- New Jersey18 studier
- New York42 studier
- North Carolina22 studier
- Ohio29 studier
- Oklahoma4 studier
- Oregon9 studier
- Pennsylvania24 studier
- South Carolina4 studier
- Tennessee15 studier
- Texas45 studier
- Utah14 studier
- Virginia10 studier
- Washington12 studier
- Wisconsin12 studier
Nyligt opdaterede studier
Officiel studietekst (engelsk)
CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)
RekruttererFase 1
Alder 12 til 75 · Alle køn · Opdateret 2. okt. 2026 · NCT02917083Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas
RekruttererFase 2
Alder 12 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT03258567Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RekruttererObservationsstudie
Alder 3 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT01441089Rutgers University Study of the Genetics of Blood Cancers
RekruttererObservationsstudieFrivillige med god helbredstilstand velkomne
Alder 18 til 110 · Alle køn · Opdateret 1. okt. 2026 · NCT07714044T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 1. okt. 2026 · NCT06343311Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
RekruttererObservationsstudie
Alder 0 til 38 · Alle køn · Opdateret 1. okt. 2026 · NCT06131801CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
RekruttererFase 1/2
Alder 3 til 39 · Alle køn · Opdateret 30. sep. 2026 · NCT05442515A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 30. sep. 2026 · NCT07192471A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 30. sep. 2026 · NCT07015242A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy
RekruttererFase 2
1 Month – 17 Years · Alle køn · Opdateret 30. sep. 2026 · NCT04570423Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 29. sep. 2026 · NCT07583810Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer
RekruttererObservationsstudie
Alder 18 til 120 · Alle køn · Opdateret 28. sep. 2026 · NCT00006518A Resilience-Based Approach to Improve Long-term Quality of Life in Post-treatment Lymphoma Survivorship
Rekrutterer
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT07013435Increasing Resiliency Among Early Post-Treatment Lymphoma Survivors
Rekrutterer
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT07014293Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT03418038Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
RekruttererObservationsstudie
Alder 18 til 110 · Alle køn · Opdateret 28. sep. 2026 · NCT00923507Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
RekruttererFase 1/2
Alder 18 til 120 · Alle køn · Opdateret 28. sep. 2026 · NCT03223610A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
RekruttererFase 1/2
Op til 25 år · Alle køn · Opdateret 25. sep. 2026 · NCT04094610Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
RekruttererFase 1
24 Months – 18 Years · Alle køn · Opdateret 25. sep. 2026 · NCT06441331Epco, Zanu, Ritux for R/R FL or MZL
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT06563596Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
RekruttererTidlig fase 1
Alder 18 og opefter · Alle køn · Opdateret 24. sep. 2026 · NCT06398457Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 24. sep. 2026 · NCT02974647CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma
RekruttererFase 2
Alder 18 til 99 · Alle køn · Opdateret 24. sep. 2026 · NCT04083495Precise Oncology Interventions in Nutrition and Training (OnPoint)
RekruttererFrivillige med god helbredstilstand velkomne
Alder 18 og opefter · Alle køn · Opdateret 23. sep. 2026 · NCT06534918Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 23. sep. 2026 · NCT04301076Fra ClinicalTrials.gov, data hentet 3. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.